2025年4月14日,复旦大学余科达团队在PNAS(IF=9.4)在线发表题为“SNX10 deficiency impairs sensitivity to anti-HER2 antibody–drug conjugates via altering HER2 trafficking in HER2-positive breast cancer”的研究论文。该研究通过分析来自...
[3] Xu B, Li W, Zhang Q, et al. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, dou...
For the past several years, the addition of trastuzumab to chemotherapy has become the standard of care for patients with metastatic, HER2-positive breast cancer; the results of several large, adjuvant trials also support its use in the adjuvant setting. Currently, clinical trials evaluating the ...
GRB2:HER2 阳性乳腺癌脑转移的关键 “推手”—— 解开肿瘤侵袭新机制 《Scientific Reports》:GRB2 promotes brain metastasis in HER2-positive breast cancer by regulating the Ras/MAPK pathway 编辑推荐: 乳腺癌脑转移严重威胁患者生命,HER2 阳性亚型更易发生且治疗棘手。研究人员聚焦 HER2 阳性乳腺癌,探究 GRB2...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....
2. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32. ...
Patients with small, human epidermal growth factor receptor 2 (HER2)–positive breast tumors treated with adjuvant paclitaxel and trastuzumab showed
中国医科大学附属盛京医院刘彩刚教授课题组在国际知名期刊Signal Transduction and Targeted Therapy在线发表题为“Molecular classification of hormone receptor-positive /HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategies”的论文。 大约70%的HER2阳性乳腺癌被归类为激素受体阳性/HER2阳性(HR+/...
HER2-Positive Breast Cancer In about 20% of breast cancers, the cells make too much of a protein known as HER2. These cancers tend to be aggressive and fast-growing. For women with HER2-positive breast cancers, the targeted drugtrastuzumab(Herceptin) has been shown to dramatically reduce the...
2、Schlam,Ilana,and Sandra M Swain.“HER2-positive breast cancer and tyrosine kinase inhibitors:the time is now.”NPJ breast cancer vol.7,1 56.20 May.2021,doi:10.1038/s41523-021-00265-1 3、Kenichi Inoue,et al.“Long-term outcomes of neoadjuvant trastuzumab emtansine+pertuzumab(T-DM1+P)and...